#USA #New York #Securities Law #Faruqi & Faruqi #Altimmune

Altimmune Class Action Lawsuit Overview

Faruqi & Faruqi, LLP, a distinguished national securities law firm, is currently investigating possible claims against Altimmune, Inc. (NASDAQ: ALT). Investors who acquired securities in the company between August 10, 2023, and June 25, 2025, are encouraged to assess their legal options before the impending lead plaintiff deadline on October 6, 2025.

The firm's inquiry follows alarming revelations concerning Altimmune's IMPACT Phase 2b MASH trial concerning Pemvidutide. On June 26, 2025, the company disclosed topline results that indicated a significant failure to meet statistical expectations regarding fibrosis reduction. Despite previous assertions of potential success, the trial results did not back these inflated claims, highlighting a concerning discrepancy between what was touted and the actual outcomes. The press release suggested a negative trend in the expected results, with the responses from the company indicating a lack of urgency or responsibility regarding the disappointing data.

As a consequence of this disclosure, Altimmune's stock plummeted from $7.71 to $3.61—a staggering decline of over 53% in a single trading day—a clear indication of investors' disappointment and diminishing confidence in the company's future prospects.

How to Get Involved

Investors who feel they have suffered losses from their investments in Altimmune due to these circumstances should not hesitate to reach out for more information. The process involves the selection of a lead plaintiff, who is determined to hold significant financial interest in the class action proceedings and assumes a representative role in overseeing the litigation on behalf of fellow class members.

Those wishing to take an active role and potentially serve as lead plaintiff are welcomed to engage with legal counsel of their choosing, whereas individuals preferring to remain passive participants can simply await the developments of the lawsuit without risking their chances for any potential recovery, regardless of their participation.

Additionally, Faruqi & Faruqi encourages any whistleblowers, former employees, or shareholders with knowledge regarding Altimmune's operations to contact the firm directly. The law firm assures confidentiality for all communications and offers a pathway for collective investor action.

To learn more about the class action proceedings against Altimmune, interested parties can visit www.faruqilaw.com/ALT or contact Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 (212-983-9330 ext. 1310) for personalized discussions regarding their rights and options.

Faruqi & Faruqi, established in 1995 and headquartered across various states including New York, California, Georgia, and Pennsylvania, has a notable record of securing substantial recoveries for investors. While the present case unfolds, stakeholders and potential participants are encouraged to remain informed and proactive in protecting their investments as the deadline approaches.

Importance of Legal Representation

With the complexities involved in securities litigation, navigating the legal landscape effectively requires competent representation. Faruqi & Faruqi highlights the significance of seeking professional guidance tailored to each investor's unique circumstances. This undertaking not only boosts chances of a favorable outcome but also facilitates a more comprehensive understanding of the legal proceedings ahead. As news continues to unfold regarding Altimmune's situation, timely action remains essential for affected investors.